Table 2.
Comparison of TCGA training and testing cohort.
| Characteristics | TCGA Testing Cohort N = 107 | TCGA Training Cohort N = 252 | p-Value |
|---|---|---|---|
| Age | 0.5587 | ||
| <=65 | 45 (42.06%) | 96 (38.1%) | |
| >65 | 62 (57.94%) | 156 (61.9%) | |
| Gender | 0.1973 | ||
| Female | 35 (32.71%) | 64 (25.4%) | |
| Male | 72 (67.29%) | 188 (74.6%) | |
| Grade | 1 | ||
| High | 103 (96.26%) | 239 (94.84%) | |
| Low | 4 (3.74%) | 10 (3.97%) | |
| Unknow | 0 (0%) | 3 (1.19%) | |
| Stage | 0.5564 | ||
| I-II | 31 (28.97%) | 82 (32.54%) | |
| III-IV | 76 (71.03%) | 168 (66.67%) | |
| Unknow | 0 (0%) | 2 (0.79%) | |
| T | 0.806 | ||
| T0-T2 | 30 (28.04%) | 77 (30.56%) | |
| T3-T4 | 67 (62.62%) | 156 (61.9%) | |
| Unknow | 10 (9.35%) | 19 (7.54%) | |
| M | 1 | ||
| M0 | 46 (42.99%) | 118 (46.83%) | |
| M1 | 3 (2.8%) | 8 (3.17%) | |
| Unknow | 58 (54.21%) | 126 (50%) | |
| N | 0.254 | ||
| N0-N1 | 79 (73.83%) | 172 (68.25%) | |
| N2-N3 | 17 (15.89%) | 55 (21.83%) | |
| Unknow | 11 (10.28%) | 25 (9.92%) | |
| Neoadjuvant therapy | 0.7362 | ||
| Yes | 2 (1.87%) | 8 (3.17%) | |
| No | 105 (98.13%) | 244 (96.83%) | |
| Radiotherapy | 0.9045 | ||
| Yes | 4 (3.74%) | 11 (4.37%) | |
| No | 77 (71.96%) | 166 (65.87%) | |
| Unknow | 26 (24.3%) | 75 (29.76%) |